M&A / Deals Roche doubles down on BTK with $2.3bn Nurix deal PharmaphorumRoche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.HematologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) Pharmaphorum Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology. Hematology Read full story Post navigation Previous: Lilly and Novo face off at ADA 2026 as others seek to compete in obesityNext: Incyte gobbles up Star’s Vega haematology unit in $2bn deal Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
